# A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

> **NCT02935153** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Southwest Hospital, China** · enrollment: 45 (estimated)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **BIOLOGICAL:** Anti-CD22-CAR-transduced T cells

## Key facts

- **NCT ID:** NCT02935153
- **Lead sponsor:** Southwest Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2019-10
- **Final completion:** 2020-10
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02935153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02935153, "A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02935153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*